

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number  
**WO 2005/000300 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/427**,  
31/4192, 31/4196, 31/433, A61P 35/00, 31/12, 19/02,  
11/06, 3/10, 17/00, 25/00, 25/28, 37/00

(Cambridge) Limited, Granta Park, Abington, Cambridge  
CB1 6GB (GB).

(21) International Application Number:  
PCT/GB2004/002755

(74) Agent: **WALLS, Alan, James**; Vernalis (Cambridge)  
Limited, Granta Park, Abington, Cambridge CB1 6GB  
(GB).

(22) International Filing Date: 24 June 2004 (24.06.2004)

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0315111.5 27 June 2003 (27.06.2003) GB

(71) Applicants (*for all designated States except US*): **VER-  
NALIS (CAMBRIDGE) LIMITED** [GB/GB]; Granta  
Park, Abington, Cambridge CB1 6GB (GB). **CANCER  
RESEARCH TECHNOLOGY LTD.** [GB/GB]; 61  
Lincoln's Inn Fields, London WC2A 3PX (GB). **THE  
INSTITUTE OF CANCER RESEARCH** [GB/GB];  
Royal Cancer Hospital, 123 Old Brompton Road, London  
SW7 3RP (GB).

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **CHEUNG, Kwai,  
Ming** [CN/GB]; The Institute of Cancer Research, Royal  
Cancer Hospital, 123 Old Brompton Road, London  
SW7 3RP (GB). **DYMOCK, Brian, William** [GB/GB];  
Vernalis (Cambridge) Limited, Granta Park, Abington,  
Cambridge CB1 6GB (GB). **MACDONALD, Edward**  
[GB/GB]; The Institute of Cancer Research, Royal Cancer  
Hospital, 123 Old Brompton Road, London SW7 3RP  
(GB). **DRYSDALE, Martin, James** [GB/GB]; Vernalis

Published:

- *with international search report*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: SUBSTITUTED 5-MEMBERED RING COMPOUNDS AND THEIR USE



(57) Abstract: Compound of a compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a com-  
position for inhibition of HSP90 activity: wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having  
5 ring atoms, for example 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R<sub>1</sub> R<sub>2</sub> R<sub>3</sub> are as defined in the specification  
are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such  
as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibro-  
sis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells  
against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from  
hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie /CJD, Huntingdon's and Alzheimer's disease.

WO 2005/000300 A1

## Substituted 5-Membered Ring Compounds and Their Use

This invention relates to substituted 5-membered ring compounds (carbocyclic and heterocyclic compounds having 5 ring atoms) having HSP90 inhibitory  
5 activity, to the use of such compounds in medicine, in relation to diseases which are mediated by excessive or inappropriate HSP90 activity such as cancers, and to pharmaceutical compositions containing such compounds.

### Background to the invention

10 Molecular chaperones maintain the appropriate folding and conformation of proteins and are crucial in regulating the balance between protein synthesis and degradation. They have been shown to be important in regulating many important cellular functions, such as cell proliferation and apoptosis (Jolly and Morimoto, 2000; Smith et al., 1998; Smith, 2001).

15

### Heat Shock Proteins (HSPs)

Exposure of cells to a number of environmental stresses, including heat shock, alcohols, heavy metals and oxidative stress, results in the cellular accumulation of a number of chaperones, commonly known as heat shock  
20 proteins (HSPs). Induction of HSPs protects the cell against the initial stress insult, enhances recovery and leads to maintenance of a stress tolerant state. It has also become clear, however, that certain HSPs may also play a major molecular chaperone role under normal, stress-free conditions by regulating the correct folding, degradation, localization and function of a growing list of  
25 important cellular proteins.

A number of multigene families of HSPs exist, with individual gene products varying in cellular expression, function and localization. They are classified according to molecular weight, e.g., HSP70, HSP90, and HSP27.

30

Several diseases in humans can be acquired as a result of protein misfolding (reviewed in Tytell et al., 2001; Smith et al., 1998). Hence the development of therapies which disrupt the molecular chaperone machinery may prove to be beneficial. In some conditions (e.g., Alzheimer's disease, prion diseases

and Huntington's disease), misfolded proteins can cause protein aggregation resulting in neurodegenerative disorders. Also, misfolded proteins may result in loss of wild type protein function, leading to deregulated molecular and physiological functions in the cell.

5

HSPs have also been implicated in cancer. For example, there is evidence of differential expression of HSPs which may relate to the stage of tumour progression (Martin et al., 2000; Conroy et al., 1996; Kawanishi et al., 1999; Jameel et al., 1992; Hoang et al., 2000; Lebeau et al., 1991). As a result of the involvement of HSP90 in various critical oncogenic pathways and the discovery that certain natural products with anticancer activity are targeting this molecular chaperone, the fascinating new concept has been developed that inhibiting HSP function may be useful in the treatment of cancer. The first molecular chaperone inhibitor is currently undergoing clinical trials.

15

### HSP90

HSP90 constitutes about 1-2% of total cellular protein, and is usually present in the cell as a dimer in association with one of a number of other proteins (see, e.g., Pratt, 1997). It is essential for cell viability and it exhibits dual chaperone functions (Young et al., 2001). It plays a key role in the cellular stress response by interacting with many proteins after their native conformation has been altered by various environmental stresses, such as heat shock, ensuring adequate protein folding and preventing non-specific aggregation (Smith et al., 1998). In addition, recent results suggest that HSP90 may also play a role in buffering against the effects of mutation, presumably by correcting the inappropriate folding of mutant proteins (Rutherford and Lindquist, 1998). However, HSP90 also has an important regulatory role. Under normal physiological conditions, together with its endoplasmic reticulum homologue GRP94, HSP90 plays a housekeeping role in the cell, maintaining the conformational stability and maturation of several key client proteins. These can be subdivided into three groups: (a) steroid hormone receptors, (b) Ser/Thr or tyrosine kinases (e.g., ERBB2, RAF-1, CDK4, and LCK), and (c) a collection of apparently unrelated proteins, e.g., mutant p53 and the catalytic subunit of telomerase hTERT. All of these

30

proteins play key regulatory roles in many physiological and biochemical processes in the cell. New HSP90 client proteins are continuously being identified.

- 5 The highly conserved HSP90 family in humans consists of four genes, namely the cytosolic HSP90 $\alpha$  and HSP90 $\beta$  isoforms (Hickey et al., 1989), GRP94 in the endoplasmic reticulum (Argon et al., 1999) and HSP75/TRAP1 in the mitochondrial matrix (Felts et al., 2000). It is thought that all the family members have a similar mode of action, but bind to different client proteins
- 10 depending on their localization within the cell. For example, ERBB2 is known to be a specific client protein of GRP94 (Argon et al., 1999) and type 1 tumour necrosis factor receptor (TNFR1) and RB have both been shown to be clients of TRAP1 (Song et al., 1995; Chen et al., 1996).
- 15 HSP90 participates in a series of complex interactions with a range of client and regulatory proteins (Smith, 2001). Although the precise molecular details remain to be elucidated, biochemical and X-ray crystallographic studies (Prodromou et al., 1997; Stebbins et al., 1997) carried out over the last few years have provided increasingly detailed insights into the chaperone function
- 20 of HSP90.

Following earlier controversy on this issue, it is now clear that HSP90 is an ATP-dependent molecular chaperone (Prodromou et al, 1997), with dimerization of the nucleotide binding domains being essential for ATP

25 hydrolysis, which is in turn essential for chaperone function (Prodromou et al, 2000a). Binding of ATP results in the formation of a toroidal dimer structure in which the N terminal domains are brought into closer contact with each other resulting in a conformational switch known as the 'clamp mechanism' (Prodromou and Pearl, 2000b).

30

#### Known HSP90 Inhibitors

The first class of HSP90 inhibitors to be discovered was the benzoquinone ansamycin class, which includes the compounds herbimycin A and

geldanamycin. They were shown to reverse the malignant phenotype of fibroblasts transformed by the v-*Src* oncogene (Uehara et al., 1985), and subsequently to exhibit potent antitumour activity in both *in vitro* (Schulte et al., 1998) and *in vivo* animal models (Supko et al., 1995).

5

Immunoprecipitation and affinity matrix studies have shown that the major mechanism of action of geldanamycin involves binding to HSP90 (Whitesell et al., 1994; Schulte and Neckers, 1998). Moreover, X-ray crystallographic studies have shown that geldanamycin competes at the ATP binding site and inhibits the intrinsic ATPase activity of HSP90 (Prodromou et al., 1997; Panaretou et al., 1998). This in turn prevents the formation of mature multimeric HSP90 complexes capable of chaperoning client proteins. As a result, the client proteins are targeted for degradation via the ubiquitin proteasome pathway. 17-Allylamino, 17-demethoxygeldanamycin (17AAG) retains the property of HSP90 inhibition resulting in client protein depletion and antitumour activity in cell culture and xenograft models (Schulte et al, 1998; Kelland et al, 1999), but has significantly less hepatotoxicity than geldanamycin (Page et al, 1997). 17AAG is currently being evaluated in Phase I clinical trials.

20

Radicalol is a macrocyclic antibiotic shown to reverse the malignant phenotype of v-*Src* and v-*Ha-Ras* transformed fibroblasts (Kwon et al, 1992; Zhao et al, 1995). It was shown to degrade a number of signalling proteins as a consequence of HSP90 inhibition (Schulte et al., 1998). X-ray crystallographic data confirmed that radicalol also binds to the N terminal domain of HSP90 and inhibits the intrinsic ATPase activity (Roe et al., 1998). Radicalol lacks antitumour activity *in vivo* due to the unstable chemical nature of the compound.

25

Coumarin antibiotics are known to bind to bacterial DNA gyrase at an ATP binding site homologous to that of the HSP90. The coumarin, novobiocin, was shown to bind to the carboxy terminus of HSP90, i.e., at a different site to that occupied by the benzoquinone ansamycins and radicalol which bind at the N-terminus (Marcu et al., 2000b). However, this still resulted in inhibition

30

of HSP90 function and degradation of a number of HSP90-chaperoned signalling proteins (Marcu et al., 2000a). Geldanamycin cannot bind HSP90 subsequent to novobiocin; this suggests that some interaction between the N and C terminal domains must exist and is consistent with the view that both sites are important for HSP90 chaperone properties.

A purine-based HSP90 inhibitor, PU3, has been shown to result in the degradation of signalling molecules, including ERBB2, and to cause cell cycle arrest and differentiation in breast cancer cells (Chiosis et al., 2001).

10

### HSP90 as a Therapeutic Target

Due to its involvement in regulating a number of signalling pathways that are crucially important in driving the phenotype of a tumour, and the discovery that certain bioactive natural products exert their effects via HSP90 activity, the molecular chaperone HSP90 is currently being assessed as a new target for anticancer drug development (Neckers et al., 1999).

15

The predominant mechanism of action of geldanamycin, 17AAG, and radicicol involves binding to HSP90 at the ATP binding site located in the N-terminal domain of the protein, leading to inhibition of the intrinsic ATPase activity of HSP90 (see, e.g., Prodromou et al., 1997; Stebbins et al., 1997; Panaretou et al., 1998).

20

Inhibition of HSP90 ATPase activity prevents recruitment of co-chaperones and encourages the formation of a type of HSP90 heterocomplex from which these client proteins are targeted for degradation via the ubiquitin proteasome pathway (see, e.g., Neckers et al., 1999; Kelland et al., 1999).

25

Treatment with HSP90 inhibitors leads to selective degradation of important proteins involved in cell proliferation, cell cycle regulation and apoptosis, processes which are fundamentally important in cancer.

30

Inhibition of HSP90 function has been shown to cause selective degradation of important signalling proteins involved in cell proliferation, cell cycle


regulation and apoptosis, processes which are fundamentally important and which are commonly deregulated in cancer (see, e.g., Hostein et al., 2001). An attractive rationale for developing drugs against this target for use in the clinic is that by simultaneously depleting proteins associated with the transformed phenotype, one may obtain a strong antitumour effect and achieve a therapeutic advantage against cancer versus normal cells. These events downstream of HSP90 inhibition are believed to be responsible for the antitumour activity of HSP90 inhibitors in cell culture and animal models (see, e.g., Schulte et al., 1998; Kelland et al., 1999).

#### Brief description of the invention

In copending patent applications nos. PCT/GB02/005778, GB0228417.2, GB0229618.4 and GB0309637.7, it has been shown that certain substituted pyrazoles and isoxazoles are inhibitors of HSP90 activity. Analogues of those compounds, wherein the pyrazole or isoxazole ring is replaced by other 5-membered ring systems are conformationally similar and expected to have HSP90 inhibitory activity. The present invention relates to the use of such analogous substituted 5-membered ring compounds as HSP90 inhibitors, for example for inhibition of cancer cell proliferation. A core 5-membered ring with aromatic substitution on one ring carbon atom are principle characterising features of the compounds with which the invention is concerned.

#### Detailed description of the invention


According to the present invention there is provided the use of a compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity:



wherein

ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms;

R<sub>1</sub> is attached to a first ring atom of ring A and is a group of formula (IA):




wherein in any compatible combination

- 5        Ar<sup>1</sup> is an optionally substituted aryl or heteroaryl radical,  
       Alk<sup>1</sup> and Alk<sup>2</sup> are optionally substituted divalent C<sub>1</sub>-C<sub>6</sub> alkylene or C<sub>2</sub>-C<sub>6</sub>  
       alkenylene radicals,  
       p, r and s are independently 0 or 1,  
       Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO<sub>2</sub>-, -C(=O)O-, -C(=O)NR<sup>A</sup>-,  
       10        -C(=S)NR<sup>A</sup>-, -SO<sub>2</sub>NR<sup>A</sup>-, -NR<sup>A</sup>C(=O)-, -NR<sup>A</sup>SO<sub>2</sub>- or -NR<sup>A</sup>- wherein R<sup>A</sup>  
       is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, and  
       Q is hydrogen or an optionally substituted carbocyclic or heterocyclic  
       radical;
- 15        R<sub>2</sub> is attached to a second ring atom of ring A, which is adjacent the first ring  
       atom to which R<sub>1</sub> is attached, or is absent if that ring atom is a nitrogen atom  
       which is double bonded to a neighbouring ring atom, and if not absent R<sub>1</sub> is  
       hydrogen or
- 20        (i) a group of formula (IA) as defined in relation to R<sub>1</sub>;
- (ii) a carboxamide radical; or
- (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring  
       25        carbon is optionally substituted, and/or a ring nitrogen is optionally  
       substituted by a group of formula -(Alk<sup>1</sup>)<sub>p</sub>-(Z)<sub>r</sub>-(Alk<sup>2</sup>)<sub>s</sub>-Q wherein Q,  
       Alk<sup>1</sup>, Alk<sup>2</sup>, Z, p, r and s are as defined above in relation to group (IA);  
       and
- 30        R<sub>3</sub> is attached to a third ring atom of ring A, which is adjacent the second ring  
       atom to which R<sub>2</sub> is attached, or is absent if that ring atom is a nitrogen atom  
       which is double bonded to a neighbouring ring atom, and if not absent R<sub>2</sub> is  
       hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub>  
       alkenyl, or C<sub>1</sub>-C<sub>6</sub> alkynyl; or a carboxyl, carboxamide or carboxyl ester group,




PROVIDED THAT (a) at least one of  $R_2$  and  $R_3$  is present and is other than hydrogen and (b) the compound of formula (I) is not one of formula (IA) (IB), (IC) or (ID)


5




(IA)



(IB)



(IC)



(ID)

wherein  $R_1$ ,  $R_2$ , and  $R_3$  are as defined above, and R is hydrogen or optionally substituted  $C_1$ - $C_6$  alkyl.

- 10 Many compounds and sub-classes of the class of compounds defined above in relation to formula (I) is believed to be novel, and the invention includes all novel members of that class and their salts, hydrates and solvates.

As used herein:

- 15 the term "carboxyl group" refers to a group of formula  $-COOH$ ;

the term "carboxyl ester group" refers to a group of formula  $-COOR$ , wherein R is a radical actually or notionally derived from the hydroxyl compound ROH; and

20

the term "carboxamide group" refers to a group of formula  $-CONR_aR_b$ , wherein  $-NR_aR_b$  is a primary or secondary (including cyclic) amino group actually or notionally derived from ammonia or the amine  $HNR_aR_b$ .

25

As used herein, the term " $(C_1-C_6)$ alkyl" refers to a straight or branched chain alkyl radical having from 1 to 6 carbon atoms, including for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.

As used herein the term "divalent (C<sub>1</sub>-C<sub>6</sub>)alkylene radical" means a saturated hydrocarbon chain having from 1 to 6 carbon atoms and two unsatisfied valences.

5

As used herein, the term "(C<sub>1</sub>-C<sub>6</sub>)alkenyl" refers to a straight or branched chain alkenyl radical having from 2 to 6 carbon atoms and containing at least one double bond of E or Z configuration, including for example, ethenyl and allyl.

10

As used herein the term "divalent (C<sub>2</sub>-C<sub>6</sub>)alkenylene radical" means a hydrocarbon chain having from 2 to 6 carbon atoms, at least one double bond, and two unsatisfied valences.

15 As used herein, the term "(C<sub>1</sub>-C<sub>6</sub>)alkynyl" refers to a straight or branched chain alkenyl radical having from 2 to 6 carbon atoms and containing at least one triple bond, including for example, ethynyl and prop-2-ynyl.

20 As used herein the term "cycloalkyl" refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

25 As used herein the term "cycloalkenyl" refers to a carbocyclic radical having from 3-8 carbon atoms containing at least one double bond, and includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.

As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical. Illustrative of such radicals are phenyl, biphenyl and naphthyl.

30 As used herein the term "carbocyclic" refers to a cyclic radical whose ring atoms are all carbon, and includes monocyclic aryl, cycloalkyl and cycloalkenyl radicals.

As used herein the term "heteroaryl" refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O. Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, 5 benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.

As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes 10 "heteroaryl" as defined above, and in particular means a mono-, bi- or tri-cyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical. Illustrative of such 15 radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.

20


Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with at least one substituent selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, mercapto, mercapto(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, halo 25 (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, -COOH, -COOR<sup>A</sup>, -COR<sup>A</sup>, -SO<sub>2</sub>R<sup>A</sup>, -CONH<sub>2</sub>, -SO<sub>2</sub>NH<sub>2</sub>, -CONHR<sup>A</sup>, -SO<sub>2</sub>NHR<sup>A</sup>, -CONR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>, -NH<sub>2</sub>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, -OCONH<sub>2</sub>, -OCONHR<sup>A</sup>, -OCONR<sup>A</sup>R<sup>B</sup>, -NHCOR<sup>A</sup>, -NHCOOR<sup>A</sup>, -NR<sup>B</sup>COOR<sup>A</sup>, -NH<sub>2</sub>SO<sub>2</sub>OR<sup>A</sup>, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>, -NHCONH<sub>2</sub>, -NR<sup>A</sup>CONH<sub>2</sub>, - 30 NHCONHR<sup>B</sup>, -NR<sup>A</sup>CONHR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, or -NR<sup>A</sup>CONR<sup>A</sup>R<sup>B</sup> wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>6</sub>)alkyl group. The term "optional substituent" means one of the foregoing substituent groups.

As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth  
5 metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-ethyl piperidine, dibenzylamine and the like. Those compounds (I) which are basic can form salts, including pharmaceutically or veterinarily acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or  
10 phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic and p-toluene sulphonic acids and the like.

Some compounds of the invention contain one or more actual or potential  
15 chiral centres because of the presence of asymmetric carbon atoms. The presence of several asymmetric carbon atoms gives rise to a number of diastereoisomers with R or S stereochemistry at each chiral centre. The invention includes all such diastereoisomers and mixtures thereof.


20 The Ring A

Compounds of formula (I) may include the following, wherein  $R_1$ ,  $R_2$  and  $R_3$  are as defined herein and X represents O or S:




Of the above structures, those wherein the 5-membered ring is aromatic are preferred, for example 1,2,4-tetrazolyl, or 1, 2, 3-triazole rings.

Specific structures (I) with which the invention is concerned have formulae (IE) and (IF):




(IE)



(IF)

#### 5    The radical R<sub>1</sub>

In general, it is currently preferred that the radical Ar<sup>1</sup> present in the R<sub>1</sub> group is optionally substituted phenyl, preferably with one of the optional substituents being a hydroxy group in position 2 relative to the point of attachment of the phenyl ring to the 5-membered ring. In other words, the group R<sub>1</sub> preferably has formula (IB)



(IB)

wherein Alk<sup>1</sup>, Alk<sup>2</sup>, p, r, s, Z and Q are as defined above in relation to R<sub>1</sub>, and R represents one or optional substituents. In the further discussion of R<sub>1</sub> which follows, this preference applies in addition to any other possibilities mentioned.

In the simplest structures with which the invention is concerned, each of p, r and s may be 0, and Q may be hydrogen, so that R<sub>1</sub> is optionally substituted aryl or heteroaryl. In such cases, R<sub>1</sub> may be, for example, optionally substituted phenyl, preferably 2-hydroxyphenyl which may be further substituted, for example by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy, chloro, or bromo. Currently preferred are compounds wherein R<sub>1</sub> is 2,4-dihydroxyphenyl, substituted in the 5-position by hydroxy, methyl, ethyl, methoxy, ethoxy, chloro, or bromo.

In other simple structures, p, r and s may again each be 0, and Q may be an optionally substituted carbocyclic or heterocyclic ring, for example phenyl, cyclohexyl, pyridyl, morpholino, piperidinyl, or piperazinyl ring. In such cases, Q is a direct substituent in the optionally substituted Ar<sup>1</sup> ring.

5

In more complex structures with which the invention is concerned, one or more of p, r and s may be 1, and Q may be hydrogen or an optionally substituted carbocyclic or heterocyclic ring. For example, p and/or s may be 1 and r may be 0, so that Q is linked to Ar<sup>1</sup> by an alkylene or alkenylene radical, for example a C<sub>1</sub>-C<sub>3</sub> alkylene radical, which is optionally substituted. In other cases each of p, r, and s may be 1, in which cases, Q is linked to Ar<sup>1</sup> by an alkylene or alkenylene radical which is interrupted by the hetero atom-containing Z radical. In still other cases, p and s may be 0 and r may be 1, in which case Q is linked to Ar<sup>1</sup> via the hetero atom-containing Z radical.

15

Specific examples of R<sub>1</sub> groups of the above types are present in the compounds of the Examples herein.

#### The radical R<sub>2</sub>

When R<sub>2</sub> is of type (i), i.e. a group of formula (IA), examples include phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, and thiazolyl wherein optional substituents include any of those listed above in the definition of "substituted", for example methoxy, ethoxy methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, and trifluoromethyl. Currently preferred are compounds wherein R<sub>2</sub> is phenyl substituted in the 4 position by C<sub>1</sub>-C<sub>6</sub> alkoxy such as methoxy or ethoxy, fluoro, chloro, bromo, morpholinomethyl, piperazino, N-methylpiperazino, or piperidino

25

When R<sub>2</sub> is a carboxamide radical of type (ii) above, examples include those of formula -CONR<sup>B</sup>(Alk)<sub>n</sub>R<sup>A</sup> wherein

30

Alk is a divalent alkylene, alkenylene or alkynylene radical, for example a -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH=CH-, or -CH<sub>2</sub>CCCH<sub>2</sub>- radical, and the Alk radical may be optionally substituted,

n is 0 or 1,

$R^B$  is hydrogen or a  $C_1$ - $C_6$  alkyl or  $C_2$ - $C_6$  alkenyl group, for example methyl, ethyl, n- or iso-propyl, or allyl,


$R^A$  is hydroxy or optionally substituted carbocyclic, for example hydroxy and/or chloro-substituted phenyl and 3,4 methylenedioxyphenyl; or heterocyclyl, for example pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl any of which heterocyclic rings may be substituted,

or  $R^A$  and  $R^B$  taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms, examples of such N-heterocyclic rings including morpholino, piperidinyl, piperazinyl and N-phenylpiperazinyl.


#### The radical $R_3$

$R_3$  may be, for example, hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, hydroxyethyl or a carboxamide group  $-\text{CONR}^B(\text{Alk})_n\text{R}^A$  as discussed above for  $R_2$ . Hydrogen, methyl or a carboxamide group are presently preferred.

A particular sub-set of the compounds with which this invention is concerned consists of those of formula (IE) and (IF), and their salts, solvates and hydrates;



(IE)




(IF)



wherein each R independently represents an optional substituent and each of  $R^2$  and  $R^3$  independently represents a carboxamide group.

Another particular sub-set of the compounds with which this invention is concerned consists of those of formula (IG), and their salts, solvates and hydrates:



(IG)

wherein  $R_3$  represents a carboxamide group (especially an ethylcarboxamide group  $\text{CH}_3\text{CH}_2\text{NHC}(=\text{O})-$ ),  $R_{10}$  represents  $\text{C}_1$ - $\text{C}_6$  alkoxy such as methoxy or ethoxy, fluoro, chloro, bromo, morpholinomethyl, piperazino, N-methylpiperazino, piperidino, N-methylpiperazinomethyl, or piperidinomethyl, and  $R_{11}$  represents bromo, chloro, phenyl,  $\text{C}_1$ - $\text{C}_6$  alkyl such as ethyl, isopropyl, isobutyl or tert-butyl, or phenyl( $\text{C}_1$ - $\text{C}_6$  alkyl)- such as benzyl or phenylethyl.

Specific compounds with which the invention is concerned include those of the Examples.

Compounds with which the invention is concerned may be prepared by literature methods, such as those of the preparative Examples herein, and methods analogous thereto.

The compounds of the invention are inhibitors of HSP90 and are thus useful in the treatment of diseases which are mediated by excessive or inappropriate HSP90 activity such as cancers; viral diseases such as Hepatitis C (HCV) (Waxman, 2002); Immunosuppression such as in transplantation (Bijlmakers, 2000 and Yorgin, 2000); Anti-inflammatory diseases (Bucci, 2000) such as Rheumatoid arthritis, Asthma, MS, Type I Diabetes, Lupus, Psoriasis and

Inflammatory Bowel Disease; Cystic fibrosis (Fuller, 2000); Angiogenesis-related diseases (Hur, 2002 and Kurebayashi, 2001); diabetic retinopathy, haemangiomas, psoriasis, endometriosis and tumour angiogenesis. Also an Hsp90 inhibitor of the invention may protect normal cells against

- 5 chemotherapy-induced toxicity and be useful in diseases where failure to undergo apoptosis is an underlying factor. Such an Hsp90 inhibitor may also be useful in diseases where the induction of a cell stress or heat shock protein response could be beneficial, for example, protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart (Hutter, 1996 and Trost, 1998)
- 10 and brain (Plumier, 1997 and Rajder, 2000). An Hsp90 inhibitor could also be useful in diseases where protein misfolding or aggregation is a major causal factor, for example, scrapie/CJD, Huntingdon's and Alzheimer's (Sittler, 2001; Trazelt, 1995 and Winklhofer, 2001).

- 15 Accordingly, the invention also provides:

- (i) a method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals, particularly humans, which method comprises administering to the mammal an amount of a compound of formula
- 20 (I) as defined above, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.; and
- (ii) a compound of formula (I) as defined above, or a salt hydrate or solvate thereof, for use in human or veterinary medicine, particularly in the treatment
- 25 of diseases or conditions mediated by excessive or inappropriate HSP90 activity;

- It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific
- 30 compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the causative mechanism and severity of the particular disease undergoing therapy. In general, a suitable dose for orally administrable formulations will usually be in the range of 0.1 to 3000 mg once, twice or three times per day,

or the equivalent daily amount administered by infusion or other routes. However, optimum dose levels and frequency of dosing will be determined by clinical trials as is conventional in the art.

- 5 The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral
- 10 administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica;
- 15 disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with
- 20 water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond
- 25 oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.


- For topical application to the skin, the drug may be made up into a cream,
- 30 lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceuticals such as the British Pharmacopoeia.

The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be  
5 dissolved in the vehicle.

The following examples illustrate the preparation and activities of specific compounds of the invention.


### 10 **Example 1**

#### **1-(2,4-Dihydroxy-phenyl)-5-(4-fluoro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid**



#### Step 1

### 15 **1-Azido-5-chloro-2,4-dimethoxy-benzene**




20 To a solution of concentrated  $\text{H}_2\text{SO}_4$  (5 mL) in water (15 mL), 5-chloro-2,4-dimethoxy-phenylamine (3g, 16mmol) was added, resulting a deep purple suspension. More water (15 mL) was then added and the mixture was cooled and stirred vigorously at  $0^\circ\text{C}$  in an ice-salt bath. A solution of sodium nitrite (1.2g, 17.4mmol) in water (5 mL) was added slowly and  
25 a brown solution was obtained. This solution was stirred at this temperature for an hour. After that, a solution of sodium azide (1.2g, 18.5mmol) in water (10 mL) was followed and the solution turned grey. This solution was then stirred for an hour. The grey precipitations (1.0g,

30%) formed were collected, washed with water and dried. Yellow solids formed in the filtrate were also collected, washed and dried. The second crop (1.47g, 43%) turned to light grey quickly.

5  $^1\text{H}$  NMR ( $\text{d}_6$ -acetone): 6.98 (1H, s); 6.89 (1H, s); 3.95 (3H, s) and 3.92 (3H, s)

### Step 2

10 **1-(5-Chloro-2,4-dimethoxy-phenyl)-5-(4-fluoro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid**



15 1-Azido-5-chloro-2,4-dimethoxy-benzene (0.4g, 1.9mmol), 3-(4-Fluoro-phenyl)-3-oxo-propionic acid methyl ester (0.42g, 2.2mmol) and sodium ethoxide in EtOH (70mg of sodium in 15 mL EtOH) were refluxed for 3 hours.  
20 During the reaction, the solution turned brown from dark green. After that, EtOH was evaporated off and the resulting oil was dried in vacuum. Trituration with ether (15 mL) gave light brown solids, which were removed by filtration and washed with ether. The solids then re-dissolved in  $\text{CHCl}_3$  and filtered. After evaporation of the solvent, light brown solids were obtained (0.35g,  
25 50%).


$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.20 (1H, s, masked by solvent peak); 7.10 (2H, m); 6.70 (2H, m); 6.20 (1H, s); 3.78 (3H, s) and 3.20 (3H, s)

LC retention time 6.98 minutes  $[\text{M}+\text{H}]^+$  378.1 & 380.1 (3 : 1)

30

### Step3

**1-(2,4-Dihydroxy-phenyl)-5-(4-fluoro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid**



5

1-(5-Chloro-2,4-dimethoxy-phenyl)-5-(4-fluoro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid (0.29g, 0.77mmol) was refluxed in a mixture of hydroiodic acid (5 mL), acetic acid (1 mL) and acetic anhydride (0.5 mL) for 16 hours. When cooled, water (20 mL) was added and the aqueous layer was extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with saturated sodium thiosulphate solution (2 x 15 mL) and brine (20 mL), dried with NaSO<sub>4</sub> and filtered. After evaporation of the solvent, light brown solids were obtained (0.15g, 62%). The compound was used in the next synthetic step without further purification.

<sup>1</sup>H NMR (d<sub>6</sub>-acetone): 7.48 (2H, dd, J = 9.0 and 5.4 Hz); 7.23 (1H, dm); 7.12 (2H, dd, J = 9.0 and 8.8 Hz); 6.46 (1H, d, J = 0.6 Hz) and 6.44 (1H, dd, 8.5 and 2.5 Hz)


LC retention time 5.58 minutes [M+H]<sup>+</sup> 316.1

20

### Example 2

1-(2,4-Dihydroxy-phenyl)-5-(4-fluoro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester

30




1-(2,4-Dihydroxy-phenyl)-5-(4-fluoro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid (0.15g, 0.48mmol) was refluxed in EtOH (20 mL) in the presence of 5

drops of concentrated  $\text{H}_2\text{SO}_4$  for 3 hours. After evaporation of the solvent, EtOAc (20 mL) was added. The organic layer was then washed with sat.  $\text{NaHCO}_3$  (2 x 10 mL) and brine (20 mL), dried with  $\text{NaSO}_4$  and filtered. After evaporation of the solvent, light brown semi-solids (93mg, 57%) were  
5 obtained and purified by prep. TLC ( $R_f$  = 0.73, EtOAc).

$^1\text{H}$  NMR ( $d_6$ -acetone): 8.90 (1H, s, broad); 7.46 (2H, dd,  $J$  = 9.0 and 5.4 Hz);  
7.20 (1H, dd,  $J$  = 8.6 and 0.8 Hz); 7.12 (2H, dd,  $J$  = 9.0 and 8.9 Hz); 6.46 (1H,  
d,  $J$  = 0.8 Hz); 6.44 (1H, dd, 8.6 and 2.5 Hz); 4.25 (2H, q,  $J$  = 7.0 Hz) and 1.20  
10 (3H, t,  $J$  = 7.0 Hz)  
LC retention time 6.58 minutes  $[\text{M}+\text{H}]^+$  344.1


### Example 3

1-(5-Chloro-2,4-dihydroxy-phenyl)-5-(4-fluoro-phenyl)-1H-[1,2,3]triazole-  
15 4-carboxylic acid ethyl ester



### Method:

1-(5-Chloro-2-hydroxy-4-methoxy-phenyl)-5-(4-fluoro-phenyl)-1H-  
20 [1,2,3]triazole-4-carboxylic acid ethyl ester and 1-(5-Chloro-2,4-  
dihydroxy-phenyl)-5-(4-fluoro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid  
ethyl ester



1-(5-Chloro-2,4-dimethoxy-phenyl)-5-(4-fluoro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid (38mg) was refluxed in HBr (48%, 1 mL) and acetic acid (1 mL) for 16 hours. When cooled, water (10 mL) was added and the aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic layers  
5 were then washed with brine (2 x 10 mL), dried with NaSO<sub>4</sub> and filtered. After evaporation of the solvent, the crude acid mixture was dried in vacuum and used in the next step. <sup>1</sup>Hnmr and LCMS of the crude mixture were analysed. EtOH (6 mL) and 3 drops of concentrated H<sub>2</sub>SO<sub>4</sub> were added to the above acid mixture and refluxed for 2 hours. After evaporation of the solvent, EtOAc  
10 (10 mL) was added. The organic layer was then washed with sat. NaHCO<sub>3</sub> (2 x 10 mL) and brine (2 x 10 mL), dried with NaSO<sub>4</sub> and filtered. After evaporation of the solvent, the esters were purified by prep. TLC. The mono-methoxy compound has R<sub>f</sub> = 0.52 whereas the dihydroxy compound has R<sub>f</sub> = 0.35 (EtOAc : n-hexane / 3 : 2).

15

The mono-methoxy compound:

<sup>1</sup>H NMR (d<sub>6</sub>-acetone): 7.61 (1H, s); 7.45 (2H, dd, J = 9.0 and 5.4 Hz); 7.16 (2H, dd, J = 9.0 and 8.8 Hz); 6.72 (1H, s); 4.25 (2H, q, J = 7.0 Hz); 3.56 (3H, s); and 1.22 (3H,t, J = 7 Hz)

20 LC retention time 7.24 minutes [M-H]<sup>-</sup> 390.2 & 392.1 (3 : 1)

The dihydroxy compound (Example 3)

<sup>1</sup>Hnmr (d<sub>6</sub>-acetone): 7.50 (2H, dd, J = 9.0 and 5.4 Hz); 7.48 (1H, s); 7.16 (2H, dd, J = 9.0 and 8.8 Hz); 6.66 (1H, s); 4.25 (2H, q, J = 7.0 Hz); and 1.22 (3H,t, J = 7 Hz)

25

LC retention time 7.10 minutes [M+H]<sup>+</sup> 378.1 & 380.1 (3 : 1)






30




The compounds of Examples 1-3 above were tested in the fluorescence poalarisation assay described below in the Assay section and the results are as shown in the following Table. Also tested were a number of commercially available compounds having structures with which the invention is concerned (Examples (i) – (v) in the Table). The suppliers of these commercially available compounds were Asinex Ltd (6, Schukinskaya Street, Moscow



123182, Russia) and Interbioscreen Ltd (Institutsky Prospect 7a, 142432 Chemogolovka, Russia).

5

Example	Structure	MH+	Hsp90 IC50	Source
(i)		309	B	Asinex
(ii)		287	B	Asinex
(iii)		336	A	Interbioscreen
(iv)		300	A	Interbioscreen
(v)		346	A	Interbioscreen

Example 1		350	B	
Example 2		344	B	
Example 3		378	A	


### Assay

- 5 A fluorescence polarization assay was employed for the evaluation of some of the compounds of the Examples:

#### Fluorescence Polarization Assay

- 10 Fluorescence polarization {also known as fluorescence anisotropy} measures the rotation of a fluorescing species in solution, where the larger molecule the more polarized the fluorescence emission. When the fluorophore is excited with polarized light, the emitted light is also polarized. The molecular size is proportional to the polarization of the fluorescence emission.

- 15 The fluorescein-labelled probe – RBT0045864-FAM –



binds to HSP90 {full-length human, full-length yeast or N-terminal domain HSP90} and the anisotropy {rotation of the probe:protein complex} is measured.

5

Test compound is added to the assay plate, left to equilibrate and the anisotropy measured again. Any change in anisotropy is due to competitive binding of compound to HSP90, thereby releasing probe.

10 Materials

Chemicals are of the highest purity commercially available and all aqueous solutions are made up in AR water.

- 1) Costar 96-well black assay plate #3915
- 15 2) Assay buffer of (a)100mM Tris pH7.4; (b) 20mM KCl; (c) 6mM MgCl<sub>2</sub>. Stored at room temperature.
- 3) BSA (bovine serum albumen) 10 mg/ml (New England Biolabs # B9001S)
- 4) 20 mM probe in 100 % DMSO stock concentration. Stored in the dark at RT. Working concentration is 200 nM diluted in AR water and stored at 4
- 20 °C. Final concentration in assay 80 nM.
- 5) E. coli expressed human full-length HSP90 protein, purified >95% (see, e.g., Panaretou et al., 1998) and stored in 50µL aliquots at -80°C .

Protocol

- 25 1) Add 100µl 1x buffer to wells 11A and 12A (=FP BLNK)
- 2) Prepare assay mix – all reagents are kept on ice with a lid on the bucket as the probe is light-sensitive.

		i. Final Conc <sup>n</sup>	
30	• 1x Hsp90 FP Buffer	10 ml	1x
	• BSA 10mg/ml (NEB)	5.0 µl	5 µg/ml
	• Probe 200µM	4.0 µl	80 nM
	• Human full-length Hsp90	6.25 µl	200 nM

- 3) Aliquot 100µl assay mix to all other wells
- 4) Seal plate and leave in dark at room temp for 20 minutes to equilibrate

Compound Dilution Plate – 1 x 3 dilution series

- 5        1) In a clear 96-well v-bottom plate – {# VWR 007/008/257} add 10 µl  
          100% DMSO to wells B1 to H11
- 2) To wells A1 to A11 add 17.5µl 100% DMSO
- 3) Add 2.5 µl cpd to A1. This gives 2.5 mM {50x} stock cpd – assuming  
              cpds 20 mM.
- 10        4) Repeat for wells A2 to A10. Control in columns 11 and 12.
- 5) Transfer 5 µl from row A to row B- not column 12. Mix well.
- 6) Transfer 5 µl from row B to row C. Mix well.
- 7) Repeat to row G.
- 8) Do not add any compound to row H – this is the 0 row.
- 15        9) This produces a 1x3 dilution series from 50 µM to 0.07 µM.
- 10) In well B12 prepare 20 µl of 100 µM standard compound.
- 11) After first incubation the assay plate is read on a Fusion™ α-FP plate  
              reader (Packard BioScience, Pangbourne, Berkshire, UK).
- 12) After the first read, 2 µl of diluted compound is added to each well for  
20        columns 1 to 10. In column 11 {provides standard curve} only add  
              compound B11 – H11. Add 2 µl of 100mM standard cpd to wells B12 –  
              H12 {is positive control }
- 13) The Z' factor is calculated from zero controls and positive wells. It  
              typically gives a value of 0.7 – 0.9.

25

The compounds tested in the above assay were assigned to one of two activity ranges, namely A = <10µM; B = >10µM, and those assignments are reported above.

30

REFERENCES

- Argon Y and Simen BB. 1999 "Grp94, an ER chaperone with protein and peptide binding properties", Semin. Cell Dev. Biol., Vol. 10, pp. 495-505.
- Bijlmakers M-JJE, Marsh M. 2000 "Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56lck", Molecular Biology of the Cell, Vol. 11(5), pp. 1585-1595.
- Bucci M; Roviezzo F; Cicala C; Sessa WC, Cirino G. 2000 "Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo", Brit. J. Pharmacol., Vol 131(1), pp. 13-16.
- Chen C-F, Chen Y, Dai KD, Chen P-L, Riley DJ and Lee W-H. 1996 "A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock", Mol. Cell. Biol., Vol. 16, pp. 4691-4699.
- Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Loenzino L and Rosen N. 2001 "A small molecule designed to bind to the adenine nucleotide pocket of HSP90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells", Chem. Biol., Vol. 8, pp. 289-299.
- Conroy SE and Latchman DS. 1996 "Do heat shock proteins have a role in breast cancer?", Brit. J. Cancer, Vol. 74, pp. 717-721.
- Felts SJ, Owen BAL, Nguyen P, Trepel J, Donner DB and Toft DO. 2000 "The HSP90-related protein TRAP1 is a mitochondrial protein with distinct functional properties", J. Biol. Chem., Vol. 5, pp. 3305-3312.
- Fuller W, Cuthbert AW. 2000 "Post-translational disruption of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular Chaperone complex with geldanamycin stabilizes delta F508 CFTR in the rabbit reticulocyte lysate", J. Biol. Chem., Vol 275(48), pp. 37462-37468.

- Hickey E, Brandon SE, Smale G, Lloyd D and Weber LA. 1999 "Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein", Mol. Cell. Biol., Vol. 9, pp. 2615-2626.
- Hoang AT, Huang J, Rudra-Gonguly N, Zheng J, Powell WC, Rabindron SK,  
5 Wu C and Roy-Burman P. 2000 "A novel association between the human heat shock transcription factor I (HSF1) and prostate adenocarcinoma, Am. J. Pathol., Vol. 156, pp. 857-864.
- Hostein I, Robertson D, Di Stefano F, Workman P and Clarke PA. 2001  
10 "Inhibition of signal transduction by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis", Cancer Res., Vol. 61, pp. 4003-4009.
- Hur E, Kim H-H, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee M-O, Park H. 2002 "Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1 $\alpha$ /aryl hydrocarbon receptor  
15 nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol", Mol. Pharmacol., Vol 62(5), pp. 975-982.
- Hutter et al, 1996, Circulation, Vol.94, pp.1408.
- Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC and Luqmani  
20 YA. 1992 "Clinical and biological significance of HSP89a in human breast cancer", Int. J. Cancer, Vol. 50, pp. 409-415.
- Jolly C and Morimoto RI. 2000 "Role of the heat shock response and molecular chaperones in oncogenesis and cell death", J. Natl. Cancer Inst., Vol. 92, pp. 1564-1572.
- Kawanishi K, Shiozaki H, Doki Y, Sakita I, Inoue M, Yano M, Tsujinata T,  
25 Shamma A and Monden M. 1999 "Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus", Cancer, Vol. 85, pp. 1649-1657.
- Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer  
30 BA and Harrap KR. 1993 "Preclinical antitumour evaluation of bis-acetalo-amino-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug", Cancer Research, Vol. 53, pp. 2581-2586.
- Kelland LR, Sharp SY, Rogers PM, Myers TG and Workman P. 1999 "DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,

- 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90", J. Natl. Cancer Inst., Vol. 91, pp. 1940-1949.
- 5 Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo, H. 2001 "A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1 $\alpha$  and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts", Jap. J. Cancer Res., Vol 92(12), 1342-1351.
- 10 Kwon HJ, Yoshida M, Abe K, Horinouchi S and Bepple T. 1992 "Radicicol, an agent inducing the reversal of transformed phenotype of src-transformed fibroblasts, Biosci., Biotechnol., Biochem., Vol. 56, pp. 538-539.
- 15 Lebeau J, Le Cholony C, Prosperi MT and Goubin G. 1991 "Constitutive overexpression of 89 kDa heat shock protein gene in the HBL100 mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene", Oncogene, Vol. 6, pp. 1125-1132.
- Marcu MG, Chadli A, Bouhouche I, Catelli M and Neckers L. 2000a "The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone", J. Biol. Chem., Vol. 275, pp. 37181-37186.
- 20 Marcu MG, Schulte TW and Neckers L. 2000b "Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins", J. Natl. Cancer Inst., Vol. 92, pp. 242-248.
- Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, MacKay A, O'Hare MJ, Kaelin CM, Mutter GL, Pardee AB and Sager R. 2000
- 25 "Linking gene expression patterns to therapeutic groups in breast cancer", Cancer Res., Vol. 60, pp. 2232-2238.
- Neckers L, Schulte TW and Momnaugh E. 1999 "Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity", Invest. New Drugs, Vol. 17, pp. 361-373.
- 30 Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski J, Smith A and Rodman L. 1997 "Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats", Proc. Am. Assoc. Cancer Res., Vol. 38, pp. 308.

- Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1998 "ATP binding and hydrolysis are essential to the function of the HSP90 molecular chaperone in vivo", EMBO J., Vol. 17, pp. 4829-4836.
- 5 Plumier et al, 1997, Cell. Stress Chap., Vol.2, pp.162
- Pratt WB. 1997 "The role of the HSP90-based chaperone system in signal transduction by nuclear receptors and receptors signalling via MAP kinase", Annu. Rev. Pharmacol. Toxicol., Vol. 37, pp. 297-326.
- Prodromou C and Pearl LH. 2000a "Structure and in vivo function of HSP90",  
10 Curr. Opin. Struct. Biol., Vol. 10, pp. 46-51.
- Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1997 "Identification and structural characterization of the ATP/ADP-binding site in the HSP90 molecular chaperone", Cell, Vol. 90, pp. 65-75.
- Prodromou C, Panaretou B, Chohan S, Siligardi G, O'Brien R, Ladbury JE,  
15 Roe SM, Piper PW and Pearl LH. 2000b "The ATPase cycle of HSP90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains", EMBO J., Vol. 19, pp. 4383-4392.
- Rajder et al, 2000, Ann. Neurol., Vol.47, pp.782.
- Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1999  
20 "Structural basis for inhibition of the HSP90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin", J. Med. Chem., Vol. 42, pp. 260-266.
- Rutherford SL and Lindquist S. 1998 "HSP90 as a capacitor for morphological evolution. Nature, Vol. 396, pp. 336-342.
- 25 Schulte TW, Akinaga S, Murakata T, Agatsuma T, Sugimoto S, Nakano H, Lee YS, Simen BB, Argon Y, Felts S, Toft DO, Neckers LM and Sharma SV. 1999 "Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones", Mol. Endocrinology, Vol. 13, pp. 1435-1448.
- 30 Schulte TW, Akinaga S, Soga S, Sullivan W, Sensgard B, Toft D and Neckers LM. 1998 "Antibiotic radicicol binds to the N-terminal domain of HSP90 and shares important biologic activities with geldanamycin", Cell Stress and Chaperones, Vol. 3, pp. 100-108.




- Schulte TW and Neckers LM. 1998 "The benzoquinone ansamycin 17-allylamino-17-deemthoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin", Cancer Chemother. Pharmacol., Vol. 42, pp. 273-279.
- 5 Sittler et al, 2001, Hum. Mol. Genet., Vol.10, pp.1307.
- Smith DF. 2001 "Chaperones in signal transduction", in: Molecular chaperones in the cell (P Lund, ed.; Oxford University Press, Oxford and NY), pp. 165-178.
- Smith DF, Whitesell L and Katsanis E. 1998 "Molecular chaperones: Biology and prospects for pharmacological intervention", Pharmacological Reviews, Vol. 50, pp. 493-513.
- 10 Song HY, Dunbar JD, Zhang YX, Guo D and Donner DB. 1995 "Identification of a protein with homology to hsp90 that binds the type 1 tumour necrosis factor receptor", J. Biol. Chem., Vol. 270, pp. 3574-3581.
- 15 Stebbins CE, Russo A, Schneider C, Rosen N, Hartl FU and Pavletich NP. 1997 "Crystal structure of an HSP90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent", Cell, Vol. 89, pp. 239-250.
- Supko JG, Hickman RL, Grever MR and Malspeis L. 1995 "Preclinical pharmacologic evaluation of geldanamycin as an antitumour agent", Cancer Chemother. Pharmacol., Vol. 36, pp. 305-315.
- 20 Tratzelt et al, 1995, Proc. Nat. Acad. Sci., Vol. 92, pp. 2944.
- Trost et al, 1998, J. Clin. Invest., Vol.101, pp.855.
- Tytell M and Hooper PL. 2001 "Heat shock proteins: new keys to the development of cytoprotective therapies", Emerging Therapeutic Targets, Vol. 5, pp. 267-287.
- 25 Uehara U, Hori M, Takeuchi T and Umezawa H. 1986 "Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus", Mol. Cell. Biol., Vol. 6, pp. 2198-2206.
- 30 Waxman, Lloyd H. Inhibiting hepatitis C virus processing and replication. (Merck & Co., Inc., USA). PCT Int. Appl. (2002), WO 0207761
- Winkhofer et al, 2001, J. Biol. Chem., Vol. 276, 45160.

- Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM. 1994  
"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein  
complex formation by benzoquinone ansamycins: essential role for  
stress proteins in oncogenic transformation", Proc. Natl. Acad. Sci. U S  
5 A., Vol. 91, pp. 8324-8328.
- Yorgin et al. 2000 "Effects of geldanamycin, a heat-shock protein 90-binding  
agent, on T cell function and T cell nonreceptor protein tyrosine  
kinases", J. Immunol., Vol 164(6), pp. 2915-2923.
- Young JC, Moarefi I and Hartl FU. 2001 "HSP90: a specialized but essential  
10 protein-folding tool", J. Cell. Biol., Vol. 154, pp. 267-273.
- Zhao JF, Nakano H and Sharma S. 1995 "Suppression of RAS and MOS  
transformation by radicicol", Oncogene, Vol. 11, pp. 161-173.

Claims:


1. The use of a compound of a compound of formula (I) or a salt, N-oxide,  
5 hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity:



wherein

- 10 ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms;

R<sub>1</sub> is attached to a first ring atom of ring A and is a group of formula (IA):



- 15 wherein in any compatible combination

Ar<sup>1</sup> is an optionally substituted aryl or heteroaryl radical,

Alk<sup>1</sup> and Alk<sup>2</sup> are optionally substituted divalent C<sub>1</sub>-C<sub>6</sub> alkylene or C<sub>2</sub>-C<sub>6</sub> alkenylene radicals,

p, r and s are independently 0 or 1,

- 20 Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO<sub>2</sub>-, -C(=O)O-, -C(=O)NR<sup>A</sup>-,  
-C(=S)NR<sup>A</sup>-, -SO<sub>2</sub>NR<sup>A</sup>-, -NR<sup>A</sup>C(=O)-, -NR<sup>A</sup>SO<sub>2</sub>- or -NR<sup>A</sup>- wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, and

Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;

25

R<sub>2</sub> is attached to a second ring atom of ring A, which is adjacent the first ring atom to which R<sub>1</sub> is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a neighbouring ring atom, and if not absent R<sub>1</sub> is hydrogen or

30


- (i) a group of formula (IA) as defined in relation to R<sub>1</sub>;

(ii) a carboxamide radical; or


(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula  $-(Alk^1)_p-(Z)_r-(Alk^2)_s-Q$  wherein Q,  $Alk^1$ ,  $Alk^2$ , Z, p, r and s are as defined above in relation to group (IA); and

$R_3$  is attached to a third ring atom of ring A, which is adjacent the second ring atom to which  $R_2$  is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a neighbouring ring atom, and if not absent  $R_2$  is hydrogen, optionally substituted cycloalkyl, cycloalkenyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkenyl, or  $C_1$ - $C_6$  alkynyl; or a carboxyl, carboxamide or carboxyl ester group,


PROVIDED THAT (a) at least one of  $R_2$  and  $R_3$  is present and is other than hydrogen and (b) the compound of formula (I) is not one of formula (IA) (IB), (IC) or (ID)




(IA)



(IB)



(IC)



(ID)

wherein  $R_1$ ,  $R_2$ , and  $R_3$  are as defined above, and R is hydrogen or optionally substituted  $C_1$ - $C_6$  alkyl.


2. The use as claimed in claim 1 wherein the group the ring A is aromatic.

3. The use as claimed in claim 1 or claim 2 wherein both  $R_1$  and  $R_2$  are attached to ring carbon atoms.


4. The use as claimed in claim 1 or claim 2 wherein one of  $R_1$  and  $R_2$  is attached to a ring carbon atom and the other to a ring nitrogen atom.

5. The use as claimed in claim 1 wherein the ring A is a 1,2,4-tetrazolyl ring or a 1, 2, 3-triazole ring.

6. The use as claimed in claim 1 wherein the compound of formula (I) has formula (IE) or (IF)




(IE)



(IF)

10 wherein  $R_1$ ,  $R_2$ , and  $R_3$  are as defined in claim 1

7. The use as claimed in any of the preceding claims wherein in the compound of formula (I)  $R_1$  has formula (II):



(II)


15 wherein  $Alk^1$ ,  $Alk^2$ ,  $p$ ,  $r$ ,  $s$ ,  $Z$  and  $Q$  are as defined above in relation to  $R_1$ , and  $R$  represents one or more optional substituents.

8. The use as claimed in any of the preceding claims wherein in the group  $R_1$  of the compound of formula (I) each of  $p$ ,  $r$  and  $s$  is 0, and  $Q$  is hydrogen.

20

9. The use as claimed in claim 8 wherein  $R_1$  is 2-hydroxyphenyl optionally further substituted by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy, chloro, or bromo.

25 10. The use as claimed in any of claims 1 to 8 wherein in the compound of formula (I)  $R_1$  has formula ((IIA):



wherein R represents bromo, chloro, phenyl, C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl(C<sub>1</sub>-C<sub>6</sub> alkyl)-.

11. The use as claimed in any of claims 1 to 7 wherein in the group R<sub>1</sub> of the compound of formula (I) one or more of p, r and s is 1.

12. The use as claimed in claim 11 wherein p and/or s is/are 1 and r is 0.

13. The use as claimed in claim 11 wherein each of p, r, and s is 1.

14. The use as claimed in claim 11 wherein p and s are 0 and r is 1.

15. The use as claimed in any of the preceding claims wherein R<sub>2</sub> is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.

16. The use as claimed in any of claims 1 to 14 wherein R<sub>2</sub> is optionally substituted phenyl.

17. The use as claimed in any of claims 1 to 14 wherein R<sub>2</sub> is a carboxamide radical of formula -CONR<sup>B</sup>(Alk)<sub>n</sub>R<sup>A</sup> wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1,

R<sup>B</sup> is hydrogen or a C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>2</sub>-C<sub>6</sub> alkenyl group,

$R^A$  is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

- 5 or  $R^A$  and  $R^B$  taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

- 10 18. The use as claimed claim 17 wherein

Alk is an optionally substituted  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}=\text{CH}-$ , or  $-\text{CH}_2\text{CCCH}_2-$  radical.

- 15 n is 0 or 1,

$R^B$  is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

- 20  $R^A$  is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4-methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl,

or  $R^A$  and  $R^B$  taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.

25

19. The use as claimed in claim 17 wherein n is 0,  $R^B$  is hydrogen and  $R^A$  is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.

20. The use as claimed in any of the preceding claims wherein  $R_3$  is  
30 hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, or hydroxyethyl.

21. The use as claimed in any of claims 1 to 19 wherein  $R_3$  is a carboxamide group  $-\text{CONR}^B(\text{Alk})_n\text{R}^A$  as defined in any of claims 16 to 18 in relation to  $R_2$ .

22. A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (I) as  
5 defined in any of claims 1 to 21, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.

23. The use as claimed in any of claims 1 to 21 or a method as claimed claim 21 for immunosuppression or the treatment of cancer; viral disease,  
10 inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo  
15 apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.

24. A compound of formula (I) as defined in any of claims 1 to 21, or a salt  
20 hydrate or solvate thereof, for use in human or veterinary medicine.

25. A pharmaceutical or veterinary composition comprising a compound as defined in any of claims 1 to 21, or a salt hydrate or solvate thereof, together with a pharmaceutically or veterinarily acceptable carrier.

25



# INTERNATIONAL SEARCH REPORT

In International Application No  
Filing No. GB2004/002755

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 A61K31/427 A61K31/4192 A61K31/4196 A61K31/433 A61P35/00 A61P31/12 A61P19/02 A61P11/06 A61P3/10 A61P17/00 A61P25/00 A61P25/28 A61P37/00					
According to International Patent Classification (IPC) or to both national classification and IPC					
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, BIOSIS, EMBASE, WPI Data, BEILSTEIN Data					
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>					
Category *	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
X	WO 01/34580 A (BEIGHT DOUGLAS WADE ; MCMILLEN WILLIAM THOMAS (US); LILLY CO ELI (US);) 17 May 2001 (2001-05-17) abstract page 3, line 26 - page 4, line 12 page 23, line 13 - page 31, line 9; claims 20,28; examples 1-17; table 1 page 6, line 10 - page 7, line 9				1-9, 11-14, 20,22-26
X	US 5 869 509 A (GRIBKOFF VALENTIN K ET AL) 9 February 1999 (1999-02-09) abstract column 5, line 40 - column 30, line 11 examples 11-19,21-38,40-57,61-63,65-120 claims 1-14; examples 122,126-134,136-146 ----- -/--				1-9, 11-16, 20,22-26
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.					
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the International filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *8* document member of the same patent family					
Date of the actual completion of the international search			Date of mailing of the international search report		
26 October 2004			08/11/2004		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016			Authorized officer  A. Jakobs		

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/GB2004/002755

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 43 20 801 A (FAHLBERG LIST PHARMA GMBH) 5 January 1995 (1995-01-05) abstract claims 1-3; examples 4,5; tables 1,2 -----	1-9,20, 22-26
X	EP 1 293 503 A (MERCK PATENT GMBH ; YAMANOUCHI PHARMA CO LTD (JP)) 19 March 2003 (2003-03-19) abstract page 3, line 41 - page 8, line 32 page 20, line 3 - page 42, line 39; examples 1-288 -----	1-9, 11-16, 20,22-26
X	EP 1 070 708 A (HOFFMANN LA ROCHE) 24 January 2001 (2001-01-24)  the whole document -----	1-9, 11-16, 20,22-26
X	WO 99/64415 A (KATO TOMOKI ; PFIZER PHARMA (JP); ANDO KAZUO (JP); KAWAI AKIYOSHI (JP)) 16 December 1999 (1999-12-16) abstract page 3, line 24 - page 4, line 24; claims 1-15; examples 1-198 -----	1-4,7,8, 14-18, 20-26
X	WO 03/015777 A (GIEGRICH KRISTINA ; BAUER ULRIKE (DE); DEUSCHLE ULRICH (DE); KOGL MANF) 27 February 2003 (2003-02-27)  abstract paragraphs '0014!, '0015!, '0025! - '0033! paragraph '0085!; claims 1-32; tables 3-6 -----	1-3,7-9, 11,12, 14-16, 20,22-26
X	FR 2 258 180 A (CERMOL SA) 18 August 1975 (1975-08-18)  the whole document -----	1,3,8,9, 15,16, 20,22-26
X	GB 1 406 345 A (THIEMANN CHEM PHARM FAB) 17 September 1975 (1975-09-17)  the whole document -----	1-3, 7-10,20, 22-26
X	WO 01/34198 A (BEIGHT DOUGLAS WADE ; MCMILLEN WILLIAM THOMAS (US); TEICHER BEVERLY AN) 17 May 2001 (2001-05-17) the whole document -----	1-14, 22-26
X	WO 99/40088 A (DIMENSIONAL PHARM INC) 12 August 1999 (1999-08-12)  abstract page 5, line 16 - page 6, line 10; example 196 ----- -/-	1-3,7-9, 14,15, 20,22-26

# INTERNATIONAL SEARCH REPORT

Int. Application No.  
PCI/GB2004/002755

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 489 598 A (CONNOR DAVID T ET AL) 6 February 1996 (1996-02-06)  column 2, lines 5-12; examples 1-61 -----	1-9, 11, 12, 14-16, 20, 22-26
X	WO 01/07436 A (BURNS CHRISTOPHER J ; CHOI SLEDESKI YONG MI (US); LAU WAN F (US); PAUL) 1 February 2001 (2001-02-01) abstract; example 1201 page 395, line 1 - page 397, line 14 -----	1-3, 7-9, 15, 20, 22-26
X	FEVIG JOHN M ET AL: "Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 5, 12 March 2001 (2001-03-12), pages 641-645, XP002301746 ISSN: 0960-894X the whole document -----	1-6, 8, 11, 17, 19, 21, 24-26
P, X	WO 03/101985 A (AMGEN INC ; NGUYEN THOMAS (US); NORMAN MARK H (US); WANG HUI-LING (US)) 11 December 2003 (2003-12-11) abstract page 33, line 1 - page 36, line 27; claims 1, 15-39; example 42 -----	1-4, 7-9, 14-16, 20, 22-26
P, X	WO 03/104207 A (MERCK & CO INC ; OLSON STEVEN H (US); ZHU YUPING (US); BALKOVEC JAMES) 18 December 2003 (2003-12-18)  abstract page 5, line 16 - page 16, line 21 page 58, line 1 - page 60, line 3; claims 1-29; examples 3-15 -----	1-9, 11, 12, 15, 16, 20, 22-26
P, X	WO 2004/030611 A (GIRARDET JEAN-LUC ; HERNANDEZ MARTHA A DE LA ROSA (US); GUNIC ESMIR (U)) 15 April 2004 (2004-04-15) abstract page 3, lines 18-28; tables 2, 4 -----	1-3, 5-9, 11-16, 20, 22-26

## INTERNATIONAL SEARCH REPORT

national application No.  
PCT/GB2004/002755

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claim 22 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box II.1

Although claim 22 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box II.2

Claims Nos.: -

There are two claims 17 and no claim 20. For the purposes of the search report, the second claim number 17 has been considered as claim number 18, the claim 18 has been considered as claim 19, claim 19 has been considered as claim 20.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.


# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB2004/002755

Box No: IV Text of the abstract (Continuation of item 5 of the first sheet)

Compound of a compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity:



wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example a 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R<sub>1</sub> R<sub>2</sub> R<sub>3</sub> are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis, angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie /CJD, Huntingdon's and Alzheimer's disease.

# INTERNATIONAL SEARCH REPORT

II International Application No  
PCT/GB2004/002755

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0134580	A	17-05-2001	AU 1761001 A BR 0015482 A CA 2391230 A1 CN 1387518 T EP 1263743 A1 JP 2003513962 T MX PA02004646 A WO 0134580 A1 US 6797723 B1 US 2004198779 A1	06-06-2001 25-06-2002 17-05-2001 25-12-2002 11-12-2002 15-04-2003 02-09-2002 17-05-2001 28-09-2004 07-10-2004
US 5869509	A	09-02-1999	US 6077861 A US 6271249 B1 AU 711736 B2 AU 4067997 A BR 9710793 A CN 1226803 A , B CZ 9900321 A3 EP 0915856 A1 HU 0000063 A2 JP 2000516925 T KR 2000029735 A NO 990428 A NZ 334403 A PL 331385 A1 RU 2175319 C2 TW 467902 B WO 9804135 A1 ZA 9706554 A	20-06-2000 07-08-2001 21-10-1999 20-02-1998 17-08-1999 25-08-1999 16-06-1999 19-05-1999 29-01-2001 19-12-2000 25-05-2000 29-01-1999 29-09-2000 05-07-1999 27-10-2001 11-12-2001 05-02-1998 25-01-1999
DE 4320801	A	05-01-1995	DE 4320801 A1	05-01-1995
EP 1293503	A	19-03-2003	AU 5676901 A BR 0110961 A CA 2409819 A1 EP 1293503 A1 HU 0302415 A2 NO 20025517 A SK 16242002 A3 US 2003216385 A1 CN 1429215 T CZ 20023763 A3 WO 0187855 A1 PL 359340 A1 ZA 200210245 A	26-11-2001 29-06-2004 18-11-2002 19-03-2003 28-11-2003 18-11-2002 01-04-2003 20-11-2003 09-07-2003 12-03-2003 22-11-2001 23-08-2004 18-03-2004
EP 1070708	A	24-01-2001	EP 1070708 A1 AT 257827 T AU 773463 B2 AU 4865100 A BR 0003075 A CA 2314009 A1 CN 1281852 A DE 60007697 D1 DK 1070708 T3 ES 2211420 T3 HR 20000482 A1 HU 0002792 A2	24-01-2001 15-01-2004 27-05-2004 25-01-2001 13-03-2001 21-01-2001 31-01-2001 19-02-2004 10-05-2004 16-07-2004 30-06-2001 28-09-2001

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/JP2004/002755

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1070708	A	ID 26599 A	25-01-2001
		JP 2001064263 A	13-03-2001
		NO 20003723 A	22-01-2001
		NZ 505766 A	28-03-2002
		PL 341616 A1	29-01-2001
		SG 98422 A1	19-09-2003
		TR 200002097 A2	21-02-2001
		US 6265426 B1	24-07-2001
		ZA 200003680 A	22-01-2001
WO 9964415	A 16-12-1999	AT 267196 T	15-06-2004
		AU 3841499 A	30-12-1999
		DE 69917451 D1	24-06-2004
		DK 1086097 T3	09-08-2004
		EP 1086097 A1	28-03-2001
		WO 9964415 A1	16-12-1999
		JP 2002517496 T	18-06-2002
		PT 1086097 T	31-08-2004
		US 2003225064 A1	04-12-2003
		US 2004157824 A1	12-08-2004
		US 2002045654 A1	18-04-2002
WO 03015777	A 27-02-2003	EP 1285914 A1	26-02-2003
		WO 03016280 A1	27-02-2003
		EP 1423370 A1	02-06-2004
		EP 1423111 A1	02-06-2004
		EP 1423113 A1	02-06-2004
		WO 03016288 A1	27-02-2003
		WO 03015771 A1	27-02-2003
		WO 03015777 A1	27-02-2003
		US 2003187042 A1	02-10-2003
		US 2003149087 A1	07-08-2003
		US 2003130296 A1	10-07-2003
FR 2258180	A 18-08-1975	CH 577985 A5	30-07-1976
		DE 2460664 A1	24-07-1975
		FI 750026 A	22-07-1975
		FR 2258180 A1	18-08-1975
		JP 50101356 A	11-08-1975
GB 1406345	A 17-09-1975	DE 2250343 A1	18-04-1974
		BE 805838 A1	01-02-1974
		FR 2202692 A1	10-05-1974
		NL 7313957 A ,B,	16-04-1974
		NL 7610797 A	31-01-1977
WO 0134198	A 17-05-2001	AU 1916601 A	06-06-2001
		WO 0134198 A2	17-05-2001
WO 9940088	A 12-08-1999	AT 223408 T	15-09-2002
		AU 765072 B2	11-09-2003
		AU 2666599 A	23-08-1999
		CA 2321025 A1	12-08-1999
		DE 69902754 D1	10-10-2002
		DE 69902754 T2	07-08-2003
		EP 1054886 A1	29-11-2000
		JP 2002502852 T	29-01-2002
		NZ 506507 A	29-08-2003



# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/GB2004/002755

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9940088	A		US 6562840 B1	13-05-2003
			WO 9940088 A1	12-08-1999
			US 6291514 B1	18-09-2001
			US 2001031781 A1	18-10-2001
US 5489598	A	06-02-1996	NONE	
WO 0107436	A	01-02-2001	AU 1923300 A	19-06-2000
			AU 773227 B2	20-05-2004
			AU 6462800 A	13-02-2001
			BG 106340 A	31-10-2002
			BR 0013179 A	02-04-2002
			CA 2382755 A1	01-02-2001
			CN 1420882 T	28-05-2003
			CZ 20020323 A3	15-05-2002
			EE 200200045 A	16-06-2003
			EP 1208097 A2	29-05-2002
			HR 20020076 A2	31-12-2003
			HU 0203375 A2	28-12-2002
			WO 0107436 A2	01-02-2001
			JP 2003529531 T	07-10-2003
			JP 2003508353 T	04-03-2003
			MX PA02000888 A	30-07-2002
			NO 20020214 A	02-04-2002
			PL 354998 A1	22-03-2004
			SK 1182002 A3	06-11-2002
			TR 200200225 T2	21-06-2002
			WO 0032590 A1	08-06-2000
			US 2004102450 A1	27-05-2004
			ZA 200200543 A	23-06-2003
WO 03101985	A	11-12-2003	US 2003229068 A1	11-12-2003
			WO 03101985 A1	11-12-2003
WO 03104207	A	18-12-2003	WO 03104208 A1	18-12-2003
			WO 03104207 A2	18-12-2003
			US 2004048912 A1	11-03-2004
			US 2004106664 A1	03-06-2004
WO 2004030611	A	15-04-2004	WO 2004030611 A2	15-04-2004